Literature DB >> 23588558

Adherence to preventive statin therapy according to socioeconomic position.

Helle Wallach-Kildemoes1, Morten Andersen, Finn Diderichsen, Theis Lange.   

Abstract

AIM: To explore whether long-term adherence to preventive statin therapy depends on socioeconomic position (SEP).
METHODS: A cohort of individuals without established cardiovascular disease (CVD) or diabetes initiating preventive statin therapy during 2002-2005 was followed in the individual-level Danish registries for 4 years or until censoring events (death, emigration, CVD or diabetes). Only individuals aged 40-84 years for whom information was available on the SEP indicators, education and income were included (N = 76,038). Two different aspects of poor adherence were applied as outcome measures: (1) Proportion of days covered (PDC) with medication below 80 %, assuming a daily dose of one tablet (continuity); (2) Discontinuation defined as a gap between two consecutive prescriptions exceeding 365 days (persistence). Stratum-specific logistic regression analyses were applied to estimate the odds ratio (OR) for PDC <80 % across SEP, adjusting for age and hypertension. Hazard ratio (HR) for discontinuation was estimated by Cox regression analyses.
RESULTS: Adjusting mutually for income and education, the OR for PDC <80 % decreased with increasing income. Comparing the highest income quintile with the lowest, the OR were 0.64 (95 % Confidence Interval 0.64-0.65) and 0.73 (0.73-0.74) in men aged 40-64 and 65-84 years, respectively; in women, the figures were 0.79 (0.79-0.79) and 0.95 (0.94-0.95), respectively. While observed increases in adherence with longer education in unadjusted analyses were attenuated after adjustment for income among men, the potential inverse relationship between length of education and adherence was enhanced among women. Applying discontinuation as outcome, analogous differences were demonstrated.
CONCLUSION: Adherence to preventive statin therapy in Denmark decreases with decreasing income-especially in men aged 40-64 years.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23588558     DOI: 10.1007/s00228-013-1488-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  67 in total

1.  Impact of statin copayments on adherence and medical care utilization and expenditures.

Authors:  Teresa B Gibson; Tami L Mark; Kirsten Axelsen; Onur Baser; Dale A Rublee; Kimberly A McGuigan
Journal:  Am J Manag Care       Date:  2006-12       Impact factor: 2.229

2.  Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use.

Authors:  M Alan Brookhart; Amanda R Patrick; Sebastian Schneeweiss; Jerry Avorn; Colin Dormuth; William Shrank; Boris L G van Wijk; Suzanne M Cadarette; Claire F Canning; Daniel H Solomon
Journal:  Arch Intern Med       Date:  2007-04-23

Review 3.  Non-adherence to statin therapy: a major challenge for preventive cardiology.

Authors:  T R Bates; V M Connaughton; G F Watts
Journal:  Expert Opin Pharmacother       Date:  2009-12       Impact factor: 3.889

4.  The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient.

Authors:  H T Ong
Journal:  QJM       Date:  2005-07-08

5.  Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy.

Authors:  Helle Wallach Kildemoes; Carsten Hendriksen; Morten Andersen
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-08-08       Impact factor: 2.890

Review 6.  Statin rebound or withdrawal syndrome: does it exist?

Authors:  Andres Pineda; Luigi X Cubeddu
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

7.  High persistence of statin use in a Danish population: compliance study 1993-1998.

Authors:  John Larsen; Morten Andersen; Jakob Kragstrup; Lars F Gram
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

8.  Widening socioeconomic inequalities in mortality in six Western European countries.

Authors:  Johan P Mackenbach; Vivian Bos; Otto Andersen; Mario Cardano; Giuseppe Costa; Seeromanie Harding; Alison Reid; Orjan Hemström; Tapani Valkonen; Anton E Kunst
Journal:  Int J Epidemiol       Date:  2003-10       Impact factor: 7.196

9.  Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment.

Authors:  Sebastian Schneeweiss; Amanda R Patrick; Malcolm Maclure; Colin R Dormuth; Robert J Glynn
Journal:  Circulation       Date:  2007-04-09       Impact factor: 29.690

10.  Health inequalities among British civil servants: the Whitehall II study.

Authors:  M G Marmot; G D Smith; S Stansfeld; C Patel; F North; J Head; I White; E Brunner; A Feeney
Journal:  Lancet       Date:  1991-06-08       Impact factor: 79.321

View more
  31 in total

1.  Food Insecurity and Cost-Related Medication Underuse Among Nonelderly Adults in a Nationally Representative Sample.

Authors:  Dena Herman; Patience Afulani; Alisha Coleman-Jensen; Gail G Harrison
Journal:  Am J Public Health       Date:  2015-08-13       Impact factor: 9.308

2.  Impact of Gender on Satisfaction and Confidence in Cholesterol Control Among Veterans at Risk for Cardiovascular Disease.

Authors:  Karen M Goldstein; Karen M Stechuchak; Leah L Zullig; Eugene Z Oddone; Maren K Olsen; Felicia A McCant; Lori A Bastian; Bryan C Batch; Hayden B Bosworth
Journal:  J Womens Health (Larchmt)       Date:  2017-02-13       Impact factor: 2.681

3.  Association of Statin Use with Increased Risk of Musculoskeletal Conditions: A Retrospective Cohort Study.

Authors:  Una E Makris; Carlos A Alvarez; Eric M Mortensen; Ishak A Mansi
Journal:  Drug Saf       Date:  2018-10       Impact factor: 5.606

Review 4.  Statin treatment, new-onset diabetes, and other adverse effects: a systematic review.

Authors:  Casper N Bang; Peter M Okin
Journal:  Curr Cardiol Rep       Date:  2014-03       Impact factor: 2.931

5.  Medication Nonadherence: The Role of Cost, Community, and Individual Factors.

Authors:  Ibrahim Abbass; Lee Revere; Jordan Mitchell; Ajit Appari
Journal:  Health Serv Res       Date:  2016-08-25       Impact factor: 3.402

6.  Medication adherence in secondary prevention post-myocardial infarction.

Authors:  Javier A Valle; P Michael Ho
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-12

Review 7.  Medication adherence in patients with diabetes and dyslipidemia: associated factors and strategies for improvement.

Authors:  Lucas N Marzec; Thomas M Maddox
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

8.  Data Resource Profile: The Danish National Prescription Registry.

Authors:  Anton Pottegård; Sigrun Alba Johannesdottir Schmidt; Helle Wallach-Kildemoes; Henrik Toft Sørensen; Jesper Hallas; Morten Schmidt
Journal:  Int J Epidemiol       Date:  2017-06-01       Impact factor: 7.196

Review 9.  Statin Adherence: Does Gender Matter?

Authors:  Karen M Goldstein; Leah L Zullig; Lori A Bastian; Hayden B Bosworth
Journal:  Curr Atheroscler Rep       Date:  2016-11       Impact factor: 5.113

10.  Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication.

Authors:  Helle Wallach-Kildemoes; Ebba Holme Hansen
Journal:  Eur J Clin Pharmacol       Date:  2015-07-31       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.